CD200 Specific Neutra™ Antibody Products

CD200, also known as OX2, is a cell surface glycoprotein that belongs to the immunoglobulin superfamily. It primarily functions as an immunoregulatory molecule by interacting with its receptor, CD200R, expressed on cells of the myeloid lineage such as macrophages and dendritic cells. This interaction helps in maintaining immune tolerance and controlling inflammatory responses by suppressing the activity of these cells. CD200 expression is noted in a variety of tissues, including the brain, where it plays a role in protecting neurons from immune-mediated damage.

Its Gene ID: 4345, UniProtKB ID: Q9BZZ2, OMIM ID: 300013

Structure of CD200 Molecule

CD200 is a type-1 cell membrane glycoprotein belonging to the immunoglobulin supergene family, primarily expressed on myeloid/lymphoid and epithelial cells, including many cancer cells. The protein structure of CD200 includes a single V-set and C-set Ig domain, a single transmembrane region, and a short cytoplasmic tail that notably lacks signaling motifs. This structure can promote its binding to CD200 receptor (CD200R), so that CD200 can effectively participate in cell-to-cell communication and regulate immune response.

Fig.1 CD200:CD200R1 interactions via IgSF extracellular domains.¹

Signal Pathway of CD200/CD200R in Tumor Microenvironment

CD200, when engaging with its receptor CD200R on macrophages, initiates a unique signaling cascade crucial for modulating myeloid function. Upon binding, CD200R's cytoplasmic tyrosine motif is phosphorylated, leading to the activation of the adaptor proteins DOK-1 and DOK-2. This phosphorylation further attracts SH2-containing inositol phosphatase (SHIP) and Ras GTPase-activating protein (RasGAP). These interactions suppress the MAPK signaling pathway, resulting in reduced release of proinflammatory cytokines and attenuation of immune cell activation. Unlike typical inhibitory receptors with ITIM motifs, CD200R utilizes these specific phosphatases to achieve inhibition, marking a distinct mechanism of immune regulation.

Fig.2 The interaction of CD200/CD200R in cancer cells and immune cells.²

Cancer therapy targeting CD200/CD200R

Cancer therapy targeting the CD200/CD200R axis focus on disrupting the CD200-CD200R interaction, thereby enhancing the activation of immune cells and promoting a more robust anti-tumor response. This can be achieved through the use of blocking antibodies against CD200 or CD200R, or by developing small molecule inhibitors that prevent their interaction. These therapies aim to shift the immune balance in the tumor microenvironment from a suppressive state to an activated state, potentially improving the efficacy of other immunotherapeutic strategies.

Fig.3 Cancer therapy targeting CD200-CD200R axis in preclinical and clinical model.²

Creative Biolabs is a dedicated provider of a wide range of CD200-related products and antibody services to further aid your investigation into the extensive applicability and potential biological understanding of CD200. Leveraging our top-notch neutralizing antibody and recombinant antibody technology platform, we have confidence in delivering the highest quality service. Our CD200 recombinant antibody products undergo stringent quality control and performance verification, ensuring their reliability and efficacy in various biological research and clinical applications.

REFERENCES

1. Kotwica-Mojzych, Katarzyna, Barbara Jodłowska-Jędrych, and Mariusz Mojzych. "CD200: CD200R interactions and their importance in immunoregulation." International Journal of Molecular Sciences 22.4 (2021): 1602.
2. Moon, Sun Young, et al. "Emerging Immune Checkpoint Molecules on Cancer Cells: CD24 and CD200." International Journal of Molecular Sciences 24.20 (2023): 15072.